TFX · Teleflex Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Teleflex reported Q2 with solid Vascular and Surgical growth and beat EPS, but cut full-year pro forma adjusted constant currency revenue growth guidance to 3.5%-4.5% (from 4.5%-5.5%) due to slower-than-expected interventional integration, while raising full-year adjusted EPS guidance to $6.90-$7.20 (from $6.25-$6.55) on debt reduction and share repurchases funded by the closed $1.5B OEM divestiture.
- + Raised full-year 2026 adjusted EPS guidance to $6.90-$7.20 from prior $6.25-$6.55
- + Closed OEM divestiture for ~$1.5B in proceeds, funding $700M debt paydown and additional $250M ASR
- + Repurchased 1.9M shares for $250M in Q2 at avg $130.85, with $250M ASR commencing August 7
- + Received FDA BLA approval for EZPLAZ, the first freeze-dried plasma licensed by the FDA
- + Vascular and Surgical posted strong growth in Q2 at +8.0% and +9.2% pro forma adjusted constant currency, respectively
- − Cut full-year 2026 pro forma adjusted constant currency revenue growth guidance to 3.5%-4.5% from prior 4.5%-5.5% due to interventional integration delays
- − Interventional revenue declined 1% pro forma adjusted constant currency in Q2 due to slower-than-expected VI/Biotronik integration
- − Q2 adjusted gross margin fell 280 bps YoY to 61.7% and adjusted operating margin fell 520 bps to 19.6% on tariffs and acquired VI business mix
- − VI/Biotronik integration timeline extended through 2H 2026, delaying expected ramp
- − Cut full-year 2026 GAAP EPS guidance to $2.54-$2.84
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TFX
this stock
Teleflex Inc
|
$5.17B | +3.5% | +17.2% | — | 9.4% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -27.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -16.7% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -7.5% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TFX | +1.1% | -11.1% | +6.1% | -11.1% | +3.5% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | +2.3% | -10.7% | -6.9% | -10.7% | -8.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.